RNA Insights

Dive into our team's latest insights about life sciences deal making, transaction support and value creation.

The Valuation Trap: When Accounting Standards Freeze What Should Be Fluid

The Valuation Trap: When Accounting Standards Freeze What Should Be Fluid

Why Biotech Executives and Investors Should Understand the... [read more]

What's Your Corporate RNA?

What’s Your Corporate RNA?

Data-Driven Narrative for Capital Formation in Life Sciences... [read more]

Fairness Opinions: Why Expertise Matters Now More Than Ever in Life Sciences and Healthcare

Since 2015, RNA Advisors has provided valuation, transactional... [read more]

Scott Winder joins RNA to expand its Life Science Tax and Financial Reporting Valuation Group

RNA Advisors, LLC, a leading valuation and strategic... [read more]

Client Success: Healthcare Transaction Support to Assess Value from Different Perspectives

THE SITUATION: A healthcare company with a portfolio... [read more]

Client Success: Mandatory Adoption of ASC 842 – Incremental Borrowing Rate Analysis for Private Biotech

The Situation: Adoption of ASC 842 – Lease... [read more]

Client Success: Strategic Extension for Revenue-Stage Medtech Company

THE SITUATION: A medical device company was preparing... [read more]

Client Success: Navigating Strategic Investment in Healthcare Technology

THE PROBLEM: A healthcare technology company that sells... [read more]

Client Success: Incremental Borrowing Rate Analysis for Publicly Traded, Clinical Stage Biotech

THE PROBLEM: A publicly traded clinical stage biotech... [read more]

Sign Up for Periodic Updates

Enter your email address below to receive updates from RNA Advisors.